Platelet-activating factor acetylhydrolase is increased in lung lavage fluid from patients with acute respiratory distress syndrome

ObjectivePlatelet-activating factor (PAF) is a proinflammatory phospholipid that may contribute to inflammation in the acute respiratory distress syndrome (ARDS). PAF acetylhydrolase (PAF-AH) degrades PAF and regulates its biological activity. We characterized PAF-AH in bronchoalveolar lavage fluid from ARDS patients (n = 33, 22 survivors), patients at risk for ARDS (n = 6), and healthy controls (n = 6). DesignBronchoalveolar lavage was performed during acute (<96 hrs from onset), plateau (6 to 12 days), and late (≥14 days) phases of ARDS. PatientsIntubated patients with ARDS or a risk factor for ARDS. Measurements and Main ResultsIn ARDS, total bronchoalveolar lavage PAF-AH activity was markedly increased in the acute phase (87 ± 89 mU/mL, n = 33) and then decreased in the plateau (23 ± 14 mU/mL, n = 10) and late phases (19 ± 14 mU/mL, n = 7) (p = .003). Total bronchoalveolar lavage PAF-AH activity during the acute phase of ARDS was also increased as compared with patients at risk for ARDS (16 ± 13 mU/mL, n = 6) and healthy controls (3 ± 3 mU/mL, n = 6) (p < .001). In contrast, plasma PAF-AH activities were the same in controls (3215 ± 858 mU/mL, n = 6), in patients at risk for ARDS (3606 ± 1607 mU/mL, n = 6), and during the acute phase of ARDS (3098 ± 2395 mU/mL, n = 33) (p = .18). PAF-AH mRNA was present in alveolar macrophages in the acute phase of ARDS (five of six) and in at-risk patients (two of three) but not in healthy controls. ConclusionsPAF-AH activity is increased in bronchoalveolar lavage fluid from patients with ARDS. Likely sources include leakage of plasma PAF-AH into alveoli or release of PAF-AH from injured cells; however, the presence of PAF-AH mRNA in alveolar macrophages suggests that PAF-AH may be actively synthesized in the lungs of patients with ARDS. PAF-AH activity in the lungs of ARDS patients may regulate inflammation caused by PAF and related oxidized phospholipids generated in the inflammatory response.

[1]  G. Zimmerman,et al.  The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis , 2002, Critical care medicine.

[2]  P. Jorens,et al.  Natural inhibitors of neutrophil function in acute respiratory distress syndrome , 2001, Critical care medicine.

[3]  M. Schlame,et al.  Platelet-activating factor (PAF)-acetylhydrolase and PAF-like compounds in the lung: effects of hyperoxia. , 2001, Biochimica et biophysica acta.

[4]  V. Starnes,et al.  Platelet activating factor acetylhydrolase decreases lung reperfusion injury. , 2000, The Annals of thoracic surgery.

[5]  Y. Ouchi,et al.  Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. , 1999, The Journal of clinical investigation.

[6]  G. Zimmerman,et al.  Platelet-activating Factor Acetylhydrolases* , 1997, The Journal of Biological Chemistry.

[7]  M. Triggiani,et al.  Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage. , 1997, American journal of respiratory and critical care medicine.

[8]  J. Pittet,et al.  Biological markers of acute lung injury: prognostic and pathogenetic significance. , 1997, American journal of respiratory and critical care medicine.

[9]  G. Nakos,et al.  Proteins and phospholipids in BAL from patients with hydrostatic pulmonary edema. , 1997, American journal of respiratory and critical care medicine.

[10]  F. Moore,et al.  REDUCED PAF‐ACETYLHYDROLASE ACTIVITY IS ASSOCIATED WITH POSTINJURY MULTIPLE ORGAN FAILURE , 1997, Shock.

[11]  J. Ancochea,et al.  [Bronchoalveolar lavage]. , 1997, Archivos de bronconeumologia.

[12]  G. Zimmerman,et al.  Platelet‐activating factor: a mediator for clinicians , 1995, Journal of internal medicine.

[13]  G. Zimmerman,et al.  Anti-inflammatory properties of a platelet-activating factor acetylhydrolase , 1995, Nature.

[14]  K. Steinberg,et al.  Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. , 1994, American journal of respiratory and critical care medicine.

[15]  M. Lamy,et al.  The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. , 1994, American journal of respiratory and critical care medicine.

[16]  R. Taylor,et al.  Plasma degradation of platelet‐activating factor in severely ill patients with clinical sepsis , 1994, Critical care medicine.

[17]  Y. Kondoh,et al.  Platelet‐activating factor in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome , 1992, Clinical and experimental pharmacology & physiology.

[18]  P. Barnes,et al.  NHLBI workshop summary. Platelet-activating factor: role in pulmonary injury and dysfunction and blood abnormalities. , 1992, The American review of respiratory disease.

[19]  G. Zimmerman,et al.  Human macrophages secret platelet-activating factor acetylhydrolase. , 1990, The Journal of biological chemistry.

[20]  G. Zimmerman,et al.  Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor. , 1989, The Journal of biological chemistry.

[21]  N. Voelkel,et al.  Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. , 1987, The Journal of clinical investigation.

[22]  D. Stafforini,et al.  Human plasma platelet-activating factor acetylhydrolase. Purification and properties. , 1987, The Journal of biological chemistry.